The team also elucidated well-established and controversial non-BRCA predisposition genes associated with breast or ovarian cancer.
The effort will provide individuals with genetic testing to determine if they have the disorder, and when necessary, with genetic testing counselling.
Ambry will offer ArcherDX's immune repertoire sequencing assays to biopharmaceutical customers.
Researchers from Ambry Genetics analyzed a set of DTC results sent to them for confirmation testing and found that 40 percent were false positives.
The partnership will integrate Ambry Genetics' and Invicro's technologies to expedite new drug discovery and development.
Konica Minolta paid $800 million up front for Ambry, with Ambry shareholders eligible to receive up to $200 million in future payments.
The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.
Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.
The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
Konica said that the deal represents its first step toward building a presence in the precision medicine field, with an eye toward Japan and then Europe.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.